302 related articles for article (PubMed ID: 29962408)
1. Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
Yokoyama T; Mizuguchi M
Biol Pharm Bull; 2018; 41(7):979-984. PubMed ID: 29962408
[TBL] [Abstract][Full Text] [Related]
2. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
3. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Tojo K; Sekijima Y; Kelly JW; Ikeda S
Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
[TBL] [Abstract][Full Text] [Related]
4. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
5. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
6. The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?
Zhong B; Huang X; Zheng Y; Guo X; Wu L
Future Med Chem; 2021 Dec; 13(23):2083-2105. PubMed ID: 34633220
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
9. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Almeida MR; Gales L; Damas AM; Cardoso I; Saraiva MJ
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):587-96. PubMed ID: 16266291
[TBL] [Abstract][Full Text] [Related]
10. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
13. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
14. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
16. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.
Guo X; Liu Z; Zheng Y; Li Y; Li L; Liu H; Chen Z; Wu L
Drug Des Devel Ther; 2020; 14():1057-1081. PubMed ID: 32210536
[TBL] [Abstract][Full Text] [Related]
17. Cell based screening of inhibitors of transthyretin aggregation.
Reixach N; Adamski-Werner SL; Kelly JW; Koziol J; Buxbaum JN
Biochem Biophys Res Commun; 2006 Sep; 348(3):889-97. PubMed ID: 16904635
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
19. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]